{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:30:42Z","timestamp":1773235842377,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,5,28]],"date-time":"2011-05-28T00:00:00Z","timestamp":1306540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11255-011-9991-0","type":"journal-article","created":{"date-parts":[[2011,5,27]],"date-time":"2011-05-27T06:05:22Z","timestamp":1306476322000},"page":"841-845","source":"Crossref","is-referenced-by-count":17,"title":["Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease"],"prefix":"10.1007","volume":"44","author":[{"given":"Takahito","family":"Moriyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiari","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyo","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,28]]},"reference":[{"key":"9991_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73\u201387","journal-title":"Ann Intern Med"},{"key":"9991_CR2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857\u20131863","journal-title":"Lancet"},{"key":"9991_CR3","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","volume":"16","author":"RE Schmieder","year":"2005","unstructured":"Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16:3038\u20133045","journal-title":"J Am Soc Nephrol"},{"key":"9991_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131\u2013140","journal-title":"N Engl J Med"},{"key":"9991_CR5","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Of inhibitors of the rennin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026\u20132033","journal-title":"Lancet"},{"key":"9991_CR6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2005.05.016","volume":"25","author":"RD Toto","year":"2008","unstructured":"Toto RD (2008) Treatmemt of hypertension in chronic kidney disease. Semin Nephrol 25:435\u2013439","journal-title":"Semin Nephrol"},{"key":"9991_CR7","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Paving","year":"2008","unstructured":"Paving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433\u20132446","journal-title":"N Engl J Med"},{"key":"9991_CR8","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","volume":"32","author":"F Persson","year":"2009","unstructured":"Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CDA, Schalkwijk C, Danser AHJ, Boomsam F, Frandsen E, Parving HH (2009) Renal effcts of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32:1873\u20131879","journal-title":"Diabetes Care"},{"key":"9991_CR9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/hr.2009.175","volume":"33","author":"S Ito","year":"2010","unstructured":"Ito S, Nakura N, Breton SL, Keefe D (2010) Effecacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res 33:62\u201366","journal-title":"Hypertens Res"},{"key":"9991_CR10","first-page":"3199","volume":"117","author":"ND Fisher","year":"2008","unstructured":"Fisher ND, Jan Danser AHJ, Nussberger J, Dole WP, Hollenberg NK (2008) Renal and hormonal responses to direct reninin hibition with aliskiren in healthy humans. Hypertension 117:3199\u20133205","journal-title":"Hypertension"},{"key":"9991_CR11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Mets\u00e4rinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 372:547\u2013553","journal-title":"Lancet"},{"key":"9991_CR12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"9991_CR13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.ki.5000159","volume":"69","author":"S Suissa","year":"2006","unstructured":"Suissa S, Hutchinson T, Brophy JM, Kezouh A (2006) ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 69:913\u2013919","journal-title":"Kidney Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-011-9991-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-011-9991-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-011-9991-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:59:03Z","timestamp":1559390343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-011-9991-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,28]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9991"],"URL":"https:\/\/doi.org\/10.1007\/s11255-011-9991-0","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,28]]}}}